{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:18:25Z","timestamp":1791332305000,"version":"4.3.1"},"reference-count":66,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Obsessive-compulsive and related disorders (OCRDs) encompass various neuropsychiatric conditions that cause significant distress and impair daily functioning. Although standard treatments are often effective, approximately 60% of patients may not respond adequately, underscoring the need for novel therapeutic approaches.<\/jats:p><\/jats:sec>Objective<\/jats:title>To evaluate improvement in OCRD symptoms associated with glutamatergic medications as monotherapy or as augmentation to selective serotonin reuptake inhibitors, with a focus on double-blind, placebo-controlled randomized clinical trials (RCTs).<\/jats:p><\/jats:sec>Data Sources<\/jats:title>Electronic searches were conducted in PubMed, Embase, PsycINFO, Web of Science, and Cochrane Central Register of Controlled Trials on October 16, 2024, without date limits.<\/jats:p><\/jats:sec>Study Selection<\/jats:title>Two investigators independently screened records to identify double-blind RCTs comparing glutamatergic medications with placebo for patients with OCRDs regardless of age, sex, gender, or refractoriness. Abstracts, study protocols, non-English studies, and trials involving augmentation to psychotherapy were excluded.<\/jats:p><\/jats:sec>Data Extraction and Synthesis<\/jats:title>Data were extracted and synthesized using random-effects meta-analyses. Subgroup analysis was conducted based on type of OCRD, population, refractoriness of OCRD, augmentation strategy, risk of bias, and type of glutamatergic medication. Sensitivity analysis was performed using a leave-one-out approach.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Improvement in OCRD symptoms was measured by standardized mean difference (Cohen d<\/jats:italic>). Improvement in obsessive-compulsive disorder (OCD) symptoms was measured by mean difference (reduction in Yale-Brown Obsessive Compulsive Scale [Y-BOCS] scores).<\/jats:p><\/jats:sec>Results<\/jats:title>A total of 27 RCTs (1369 participants; mean [SD] age, 31.5 [7.8] years; 65.6% female) were included. Glutamatergic medications showed a large effect size in improving OCRD symptoms (Cohen d<\/jats:italic>\u2009=\u2009\u22120.80 [95% CI, \u22121.13 to \u22120.47]; low certainty of evidence). In the 23 OCD-specific RCTs, glutamatergic medications demonstrated a significant mean reduction in Y-BOCS scores (mean difference, \u22124.17 [95% CI, \u22125.82 to \u22122.52]; moderate certainty of evidence).<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>These findings indicate that glutamatergic medications may be effective in treating OCRDs, particularly OCD. However, high heterogeneity and potential publication bias necessitate cautious interpretation. Further research with larger sample sizes is needed to explore dose-dependent effects, additional OCRD subtypes, and other promising glutamatergic medications.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2024.52963","type":"journal-article","created":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T16:00:58Z","timestamp":1735833658000},"page":"e2452963","source":"Crossref","is-referenced-by-count":25,"title":["Glutamatergic Medications for Obsessive-Compulsive and Related Disorders"],"prefix":"10.1001","volume":"8","author":[{"given":"David R. A.","family":"Coelho","sequence":"first","affiliation":[{"name":"Harvard T.H. Chan School of Public Health, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Yang","sequence":"additional","affiliation":[{"name":"Harvard T.H. Chan School of Public Health, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armiel","family":"Suriaga","sequence":"additional","affiliation":[{"name":"Harvard T.H. Chan School of Public Health, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justen","family":"Manasa","sequence":"additional","affiliation":[{"name":"Harvard T.H. Chan School of Public Health, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Bain","sequence":"additional","affiliation":[{"name":"Countway Library, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willians Fernando","family":"Vieira","sequence":"additional","affiliation":[{"name":"Department of Anatomy, Institute of Biomedical Sciences, University of S\u00e3o Paulo, S\u00e3o Paulo, SP, Brazil"},{"name":"Laboratory of Neuroimmune Interface of Pain Research, Faculdade S\u00e3o Leopoldo Mandic, Instituto S\u00e3o Leopoldo Mandic, Campinas, SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Papatheodorou","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts"},{"name":"Department of Biostatistics and Epidemiology, Rutgers School of Public Health, Piscataway, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua D.","family":"Salvi","sequence":"additional","affiliation":[{"name":"Center for OCD and Related Disorders, Massachusetts General Hospital, Boston"},{"name":"Department of Psychiatry, Harvard Medical School, Boston, Massachusetts"},{"name":"McLean Hospital, Belmont, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,1,2]]},"reference":[{"issue":"6","key":"zoi241480r2","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.comppsych.2008.04.003","article-title":"Occupational functioning and impairment in adults with body dysmorphic disorder.","volume":"49","author":"Didie","year":"2008","journal-title":"Compr Psychiatry"},{"issue":"4","key":"zoi241480r3","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.comppsych.2005.11.006","article-title":"Impact of obsessive-compulsive disorder on quality of life.","volume":"47","author":"Eisen","year":"2006","journal-title":"Compr Psychiatry"},{"issue":"8","key":"zoi241480r4","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.janxdis.2010.06.004","article-title":"Quality of life and clinical severity in pathological skin picking and trichotillomania.","volume":"24","author":"Odlaug","year":"2010","journal-title":"J Anxiety Disord"},{"issue":"3","key":"zoi241480r5","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.pnpbp.2005.11.001","article-title":"The descriptive epidemiology of obsessive-compulsive disorder.","volume":"30","author":"Fontenelle","year":"2006","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"6","key":"zoi241480r6","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1001\/archpsyc.62.6.593","article-title":"Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication.","volume":"62","author":"Kessler","year":"2005","journal-title":"Arch Gen Psychiatry"},{"issue":"4","key":"zoi241480r7","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1017\/S1092852900016436","article-title":"The prevalence of body dysmorphic disorder in the United States adult population.","volume":"13","author":"Koran","year":"2008","journal-title":"CNS Spectr"},{"issue":"1","key":"zoi241480r8","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1111\/j.1742-1241.2006.01167.x","article-title":"Diagnosis and treatment of obsessive-compulsive disorder and related disorders.","volume":"61","author":"Dell\u2019Osso","year":"2007","journal-title":"Int J Clin Pract"},{"issue":"2","key":"zoi241480r9","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1586\/ern.12.160","article-title":"Augmentation strategies in obsessive-compulsive disorder.","volume":"13","author":"Arumugham","year":"2013","journal-title":"Expert Rev Neurother"},{"key":"zoi241480r10","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.conb.2014.08.008","article-title":"Striatal circuits, habits, and implications for obsessive-compulsive disorder.","volume":"30","author":"Burgui\u00e8re","year":"2015","journal-title":"Curr Opin Neurobiol"},{"issue":"4","key":"zoi241480r11","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.pbb.2011.10.007","article-title":"The role of glutamate signaling in the pathogenesis and treatment of obsessive-compulsive disorder.","volume":"100","author":"Wu","year":"2012","journal-title":"Pharmacol Biochem Behav"},{"issue":"6","key":"zoi241480r12","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1001\/jamapsychiatry.2013.173","article-title":"Abnormally high degree connectivity of the orbitofrontal cortex in obsessive-compulsive disorder.","volume":"70","author":"Beucke","year":"2013","journal-title":"JAMA Psychiatry"},{"issue":"4","key":"zoi241480r13","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1017\/S0954579408000606","article-title":"The neural bases of obsessive-compulsive disorder in children and adults.","volume":"20","author":"Maia","year":"2008","journal-title":"Dev Psychopathol"},{"issue":"1","key":"zoi241480r14","doi-asserted-by":"publisher","first-page":"132","DOI":"10.3171\/2016.1.JNS15601","article-title":"Role of the dorsal anterior cingulate cortex in obsessive-compulsive disorder: converging evidence from cognitive neuroscience and psychiatric neurosurgery.","volume":"126","author":"McGovern","year":"2017","journal-title":"J Neurosurg"},{"issue":"5","key":"zoi241480r15","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2011.5","article-title":"Basal ganglia dysfunction in OCD: subthalamic neuronal activity correlates with symptoms severity and predicts high-frequency stimulation efficacy.","volume":"1","author":"Welter","year":"2011","journal-title":"Transl Psychiatry"},{"issue":"1","key":"zoi241480r16","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1097\/YCO.0000000000000017","article-title":"Obsessive compulsive disorder and the glutamatergic system.","volume":"27","author":"Kariuki-Nyuthe","year":"2014","journal-title":"Curr Opin Psychiatry"},{"issue":"6","key":"zoi241480r17","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1055\/s-0043-118665","article-title":"Role of glutamatergic system in obsessive-compulsive disorder with possible therapeutic implications.","volume":"51","author":"Vlcek","year":"2018","journal-title":"Pharmacopsychiatry"},{"issue":"6","key":"zoi241480r18","doi-asserted-by":"publisher","first-page":"308","DOI":"10.3928\/00485713-20150602-06","article-title":"Glutamate modulators in the treatment of obsessive-compulsive disorder.","volume":"45","author":"Pittenger","year":"2015","journal-title":"Psychiatr Ann"},{"issue":"2","key":"zoi241480r19","doi-asserted-by":"publisher","first-page":"149","DOI":"10.4103\/0972-6748.132930","article-title":"An open-label trial of memantine in treatment-resistant obsessive-compulsive disorder.","volume":"22","author":"Bakhla","year":"2013","journal-title":"Ind Psychiatry J"},{"issue":"1","key":"zoi241480r20","doi-asserted-by":"publisher","first-page":"12","DOI":"10.9758\/cpn.2015.13.1.12","article-title":"N-acetyl cysteine in the treatment of obsessive compulsive and related disorders: a systematic review.","volume":"13","author":"Oliver","year":"2015","journal-title":"Clin Psychopharmacol Neurosci"},{"issue":"1","key":"zoi241480r21","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s40360-021-00534-6","article-title":"Glutamatergic medications as adjunctive therapy for moderate to severe obsessive-compulsive disorder in adults: a systematic review and meta-analysis.","volume":"22","author":"Hadi","year":"2021","journal-title":"BMC Pharmacol Toxicol"},{"issue":"12","key":"zoi241480r22","doi-asserted-by":"publisher","first-page":"e1576","DOI":"10.4088\/JCP.15r10164","article-title":"Glutamatergic agents as add-on medication for the treatment of obsessive-compulsive disorder: a systematic review and meta-analysis.","volume":"77","author":"Laoutidis","year":"2016","journal-title":"J Clin Psychiatry"},{"key":"zoi241480r23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocrd.2020.100529","article-title":"Efficacy and safety of N-acetylcysteine as add-on therapy in the treatment of obsessive-compulsive disorder: a systematic review and meta-analysis.","volume":"25","author":"Gadallah","year":"2020","journal-title":"J Obsessive Compuls Relat Disord"},{"key":"zoi241480r24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocrd.2019.100481","article-title":"Augmentation therapy of N-acetylcysteine for OCD: a meta-analysis of double-blind, randomized, placebo-controlled trials.","volume":"23","author":"Noskova","year":"2019","journal-title":"J Obsessive Compuls Relat Disord"},{"key":"zoi241480r25","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2019.112602","article-title":"A systematic review and meta-analysis: memantine augmentation in moderate to severe obsessive-compulsive disorder.","volume":"282","author":"Modarresi","year":"2019","journal-title":"Psychiatry Res"},{"issue":"11","key":"zoi241480r27","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1001\/archpsyc.1989.01810110048007","article-title":"The Yale-Brown Obsessive Compulsive Scale, I: development, use, and reliability.","volume":"46","author":"Goodman","year":"1989","journal-title":"Arch Gen Psychiatry"},{"issue":"6","key":"zoi241480r28","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1097\/00004583-199706000-00023","article-title":"Children\u2019s Yale-Brown Obsessive Compulsive Scale: reliability and validity.","volume":"36","author":"Scahill","year":"1997","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"3-4","key":"zoi241480r29","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1159\/000289003","article-title":"The Massachusetts General Hospital (MGH) Hairpulling Scale, 1: development and factor analyses.","volume":"64","author":"Keuthen","year":"1995","journal-title":"Psychother Psychosom"},{"issue":"6","key":"zoi241480r30","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/S0022-3999(01)00215-X","article-title":"The Skin Picking Scale: scale construction and psychometric analyses.","volume":"50","author":"Keuthen","year":"2001","journal-title":"J Psychosom Res"},{"issue":"3","key":"zoi241480r31","doi-asserted-by":"publisher","first-page":"236","DOI":"10.14744\/DAJPNS.2021.00143","article-title":"Yale-Brown Obsessive Compulsive Scale modified for neurotic excoriation: validity and reliability study of Turkish version.","volume":"34","author":"Aydin","year":"2021","journal-title":"J Psychiatry Neurol Sci"},{"key":"zoi241480r32","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.jad.2019.04.007","article-title":"Saving Inventory\u2013Revised: psychometric performance across the lifespan.","volume":"252","author":"Kellman-McFarlane","year":"2019","journal-title":"J Affect Disord"},{"issue":"2","key":"zoi241480r33","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1002\/sim.8781","article-title":"Evaluation of various estimators for standardized mean difference in meta-analysis.","volume":"40","author":"Lin","year":"2021","journal-title":"Stat Med"},{"issue":"7109","key":"zoi241480r35","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test.","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"6","key":"zoi241480r36","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1097\/JCP.0b013e318272677d","article-title":"N-acetylcysteine add-on treatment in refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial.","volume":"32","author":"Afshar","year":"2012","journal-title":"J Clin Psychopharmacol"},{"issue":"10","key":"zoi241480r37","first-page":"976","article-title":"Topiramate augmentation in refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial.","volume":"19","author":"Afshar","year":"2014","journal-title":"J Res Med Sci"},{"issue":"4","key":"zoi241480r38","doi-asserted-by":"publisher","DOI":"10.1002\/hup.2584","article-title":"L-carnosine as an adjuvant to fluvoxamine in treatment of obsessive compulsive disorder: a randomized double-blind study.","volume":"32","author":"Arabzadeh","year":"2017","journal-title":"Hum Psychopharmacol"},{"issue":"1","key":"zoi241480r39","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s12888-021-03642-z","article-title":"Memantine augmentation of sertraline in the treatment of symptoms and executive function among patients with obsessive-compulsive disorder: a double-blind placebo-controlled, randomized clinical trial.","volume":"22","author":"Askari","year":"2022","journal-title":"BMC Psychiatry"},{"issue":"3","key":"zoi241480r40","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.jaac.2012.12.020","article-title":"N-acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled add-on trial.","volume":"52","author":"Bloch","year":"2013","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"11","key":"zoi241480r41","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1177\/0269881111431751","article-title":"Lamotrigine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study.","volume":"26","author":"Bruno","year":"2012","journal-title":"J Psychopharmacol"},{"issue":"7","key":"zoi241480r42","doi-asserted-by":"publisher","first-page":"e766","DOI":"10.4088\/JCP.16m11101","article-title":"Randomized, double-blind, placebo-controlled trial of N-acetylcysteine augmentation for treatment-resistant obsessive-compulsive disorder.","volume":"78","author":"Costa","year":"2017","journal-title":"J Clin Psychiatry"},{"issue":"8","key":"zoi241480r43","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1111\/pcn.12394","article-title":"Riluzole in augmentation of fluvoxamine for moderate to severe obsessive-compulsive disorder: randomized, double-blind, placebo-controlled study.","volume":"70","author":"Emamzadehfard","year":"2016","journal-title":"Psychiatry Clin Neurosci"},{"issue":"11","key":"zoi241480r44","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1111\/pcn.12430","article-title":"Minocycline combination therapy with fluvoxamine in moderate-to-severe obsessive-compulsive disorder: a placebo-controlled, double-blind, randomized trial.","volume":"70","author":"Esalatmanesh","year":"2016","journal-title":"Psychiatry Clin Neurosci"},{"issue":"2","key":"zoi241480r45","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.jpsychires.2012.09.015","article-title":"Memantine add-on in moderate to severe obsessive-compulsive disorder: randomized double-blind placebo-controlled study.","volume":"47","author":"Ghaleiha","year":"2013","journal-title":"J Psychiatr Res"},{"issue":"2","key":"zoi241480r46","first-page":"134","article-title":"Efficacy of N-acetylcysteine augmentation on obsessive compulsive disorder: a multicenter randomized double blind placebo controlled clinical trial.","volume":"12","author":"Ghanizadeh","year":"2017","journal-title":"Iran J Psychiatry"},{"issue":"7","key":"zoi241480r47","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1001\/archgenpsychiatry.2009.60","article-title":"N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a double-blind, placebo-controlled study.","volume":"66","author":"Grant","year":"2009","journal-title":"Arch Gen Psychiatry"},{"issue":"4","key":"zoi241480r48","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1097\/JCP.0b013e3181e617a1","article-title":"A double-blind, placebo-controlled trial of lamotrigine for pathological skin picking: treatment efficacy and neurocognitive predictors of response.","volume":"30","author":"Grant","year":"2010","journal-title":"J Clin Psychopharmacol"},{"issue":"5","key":"zoi241480r49","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1001\/jamapsychiatry.2016.0060","article-title":"N-acetylcysteine in the treatment of excoriation disorder: a randomized clinical trial.","volume":"73","author":"Grant","year":"2016","journal-title":"JAMA Psychiatry"},{"issue":"6","key":"zoi241480r50","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1038\/npp.2013.343","article-title":"12-Week, placebo-controlled trial of add-on riluzole in the treatment of childhood-onset obsessive-compulsive disorder.","volume":"39","author":"Grant","year":"2014","journal-title":"Neuropsychopharmacology"},{"issue":"6","key":"zoi241480r51","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.jpsychires.2008.10.007","article-title":"Adjunctive glycine in the treatment of obsessive-compulsive disorder in adults.","volume":"43","author":"Greenberg","year":"2009","journal-title":"J Psychiatr Res"},{"issue":"4","key":"zoi241480r52","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1007\/s00213-013-3067-z","article-title":"In a double-blind, randomized and placebo-controlled trial, adjuvant memantine improved symptoms in inpatients suffering from refractory obsessive-compulsive disorders (OCD).","volume":"228","author":"Haghighi","year":"2013","journal-title":"Psychopharmacology (Berl)"},{"issue":"2","key":"zoi241480r53","first-page":"104","article-title":"Lamotrigine augmentation versus placebo in serotonin reuptake inhibitors\u2013?resistant obsessive-compulsive disorder: a randomized controlled trial.","volume":"11","author":"Khalkhali","year":"2016","journal-title":"Iran J Psychiatry"},{"issue":"1","key":"zoi241480r54","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1089\/cap.2019.0041","article-title":"N-acetylcysteine for pediatric obsessive-compulsive disorder: a small pilot study.","volume":"30","author":"Li","year":"2020","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"6","key":"zoi241480r55","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1055\/s-0043-120268","article-title":"Memantine augmentation improves symptoms in serotonin reuptake inhibitor\u2013refractory obsessive-compulsive disorder: a randomized controlled trial.","volume":"51","author":"Modarresi","year":"2018","journal-title":"Pharmacopsychiatry"},{"issue":"11","key":"zoi241480r56","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1017\/S1092852912000065","article-title":"Topiramate augmentation in resistant OCD: a double-blind placebo-controlled clinical trial.","volume":"15","author":"Mowla","year":"2010","journal-title":"CNS Spectr"},{"issue":"4","key":"zoi241480r57","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1017\/S1092852919001500","article-title":"Pregabalin augmentation for resistant obsessive-compulsive disorder: a double-blind placebo-controlled clinical trial.","volume":"25","author":"Mowla","year":"2020","journal-title":"CNS Spectr"},{"issue":"4","key":"zoi241480r58","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1111\/pcn.12803","article-title":"Amantadine as adjuvant therapy in the treatment of moderate to severe obsessive-compulsive disorder: a double-blind randomized trial with placebo control.","volume":"73","author":"Naderi","year":"2019","journal-title":"Psychiatry Clin Neurosci"},{"issue":"2","key":"zoi241480r59","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1111\/jcpt.12370","article-title":"N-acetylcysteine augmentation therapy for moderate-to-severe obsessive-compulsive disorder: randomized, double-blind, placebo-controlled trial.","volume":"41","author":"Paydary","year":"2016","journal-title":"J Clin Pharm Ther"},{"issue":"8","key":"zoi241480r60","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.4088\/JCP.14m09123","article-title":"Riluzole augmentation in treatment-refractory obsessive-compulsive disorder: a pilot randomized placebo-controlled trial.","volume":"76","author":"Pittenger","year":"2015","journal-title":"J Clin Psychiatry"},{"issue":"9","key":"zoi241480r61","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s40263-015-0272-9","article-title":"N-acetyl cysteine (NAC) in the treatment of obsessive-compulsive disorder: a 16-week, double-blind, randomised, placebo-controlled study.","volume":"29","author":"Sarris","year":"2015","journal-title":"CNS Drugs"},{"key":"zoi241480r62","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2022.110550","article-title":"N-acetyl cysteine (NAC) augmentation in the treatment of obsessive-compulsive disorder: a phase III, 20-week, double-blind, randomized, placebo-controlled trial.","volume":"117","author":"Sarris","year":"2022","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"8","key":"zoi241480r63","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.2174\/1570159X19666201230144109","article-title":"The multifaceted therapeutic role of N-acetylcysteine (NAC) in disorders characterized by oxidative stress.","volume":"19","author":"Raghu","year":"2021","journal-title":"Curr Neuropharmacol"},{"issue":"1","key":"zoi241480r64","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.coph.2005.09.007","article-title":"Mechanism of action of memantine.","volume":"6","author":"Johnson","year":"2006","journal-title":"Curr Opin Pharmacol"},{"issue":"3","key":"zoi241480r65","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1017\/S1461145712000429","article-title":"Neuroprotective effects of the mood stabilizer lamotrigine against glutamate excitotoxicity: roles of chromatin remodelling and Bcl-2 induction.","volume":"16","author":"Leng","year":"2013","journal-title":"Int J Neuropsychopharmacol"},{"issue":"4","key":"zoi241480r66","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1111\/j.1471-4159.2005.03259.x","article-title":"Topiramate reduces AMPA-induced Ca2+ transients and inhibits GluR1 subunit phosphorylation in astrocytes from primary cultures.","volume":"94","author":"Angehagen","year":"2005","journal-title":"J Neurochem"},{"key":"zoi241480r1","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2013","edition":"5th ed"},{"key":"zoi241480r34","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins"},{"key":"zoi241480r26","unstructured":"Covidence. Veritas Health Innovation. Accessed October 16, 2024. www.covidence.org"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2828636\/coelho_2025_oi_241480_1738603006.48027.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T16:01:59Z","timestamp":1739203319000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2828636"}},"subtitle":["A Systematic Review and Meta-Analysis"],"short-title":[],"issued":{"date-parts":[[2025,1,2]]},"references-count":66,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.52963","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,2]]}}}